PoreWise Aveeno · Cleansers
Daily Face Cleanser Foaming Gel
Product
- Brand:
- Aveeno
- Product type:
- Cleansers
- Last checked:
- 2026-10-30
- Formula version:
- Pack label · 2026-10-30
- Fragrance & alcohol:
- Fragrance-free · Alcohol-free
15 ingredients on this list · WATER at number 1 · Cocamidopropyl Betaine at number 2 · PEG-80 SORBITAN LAURATE at number 3
Product description
A foaming gel face cleanser with cocamidopropyl betaine and decyl glucoside, plus oat flour and niacinamide.
Full ingredient list
Kept exactly as the source printed it, including spelling in the original.
- 1 WATER
- 2 COCAMIDOPROPYL BETAINE
- 3 PEG-80 SORBITAN LAURATE
- 4 DECYL GLUCOSIDE
- 5 AVENA SATIVA (OAT) KERNEL FLOUR
- 6 PANTHENOL
- 7 NIACINAMIDE
- 8 ACRYLATES/C10-30 ALKYL ACRYLATE CROSSPOLYMER
- 9 COCO-GLUCOSIDE
- 10 GLYCERYL OLEATE
- 11 PHENOXYETHANOL
- 12 SODIUM BENZOATE
- 13 ETHYLHEXYLGLYCERIN
- 14 TETRASODIUM GLUTAMATE DIACETATE
- 15 SODIUM HYDROXIDE
Original label text
Water, Cocamidopropyl Betaine, Peg-80 Sorbitan Laurate, Decyl Glucoside, Avena Sativa (Oat) Kernel Flour, Panthenol, Niacinamide, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Coco-Glucoside, Glyceryl Oleate, Phenoxyethanol, Sodium Benzoate, Ethylhexylglycerin, Tetrasodium Glutamate Diacetate, Sodium Hydroxide
Ingredient analysis
NIACINAMIDE · Actives · NIACINAMIDE · Barrier lipids · PANTHENOL · Humectants
Barrier lipids
1Lipids that occur naturally in the skin barrier (ceramides, cholesterol, fatty acids).
Cleansing agents
2Lift oil and dirt so they can be rinsed away with water.
Preservatives
3Inhibit microbial growth so the product stays safe to use.
Soothing agents
3Used to reduce the sensation of irritation or discomfort.
Other
3Use on the ingredient list: see the product ingredient list.
Evidence
- Skin effect Human trial Certainty: Moderate Primary source
In a randomized, placebo-controlled split-face study of 30 healthy Japanese women, a cosmetic containing 4% niacinamide reduced the skin-surface average roughness (Ra) value significantly more than the niacinamide-free control site after 8 weeks (P<0.05).
Who it applies to: Skin-surface roughness measured by replica profilometry (Ra).
Study limits: Measured at the eye area on a photoaged/wrinkle cohort; the endpoint is surface roughness.
- Skin effect Human trial Certainty: Moderate Primary source
In 20 people with Fitzpatrick skin types IV-V, a broad-spectrum sunscreen containing sclareolide and niacinamide significantly prevented experimentally induced post-inflammatory hyperpigmentation: in stripped, exposed zones the protected skin improved by +5.96 ITA degrees versus -9.88 in unprotected skin (net protection about 16 ITA degrees, p < 0.001).
Who it applies to: People with darker skin phototypes (IV-V) prone to post-inflammatory hyperpigmentation, applying the sunscreen daily for 20 days under UV and visible-light exposure.
Study limits: Small sample (20), within-subject controlled model of experimentally induced pigmentation; the abstract calls for comparative studies with and; industry involvement.
- Skin effect Human trial Certainty: Moderate Primary source
In 72 women with visible signs of ageing, a niacinamide-containing biomimetic lamellar cream significantly improved the Cutometer R5 elasticity parameter, wrinkle score, TEWL and corneometer values over 4 weeks compared against the untreated side.
Who it applies to: Women with visible signs of ageing, applying the cream twice daily for 4 weeks.
Study limits: Grading of high-resolution images failed to detect improvements in skin texture; proof-of-concept studies.
- Skin effect Human trial Certainty: Moderate Primary source
In 91 women with melasma, a skincare routine containing vitamin B3 (niacinamide) and 2-mercaptonicotinyl glycine significantly reduced MASI after 3 months, with roughly 38-41% reduction by 6 months.
Who it applies to: Women aged about 44 with melasma, phototypes III-IV, using the routine twice daily with daily SPF50+ sunscreen.
Study limits: A clinically relevant difference favoured Kligman's triple combination in the first 3 months; industry-funded; skin radiance and fine wrinkles also improved.
- Skin effect Human trial Certainty: Moderate Primary source
In a randomized, double-blind, placebo-controlled split-face trial of 52 Taiwanese subjects, 4% niacinamide alone significantly reduced instrument-measured pore counts at week 8, and 4% niacinamide with 0.03% kinetin produced persistent significant reductions in pore, spot, wrinkle and evenness counts at weeks 8 and 12.
Who it applies to: Instrument-measured facial pore counts over 8-12 weeks.
Study limits: The niacinamide-group showed significant pore reduction at week 8; 'pore counts' is an instrument parameter.
- Skin effect Human trial Certainty: Moderate Primary source
In a double-blind, placebo-controlled trial of 100 Japanese subjects, a 2% niacinamide moisturiser significantly lowered sebum excretion rate after 2 and 4 weeks; in a separate 30-person Caucasian split-face study it significantly reduced casual sebum level after 6 weeks.
Who it applies to: Adults with facial sebum concerns applying a 2% niacinamide moisturiser for 2 to 6 weeks; measured with sebumeter-based sebum excretion rate and casual sebum level.
Study limits: The effect differs by measured endpoint and population.
- Skin effect Human trial Certainty: Moderate Primary source
In 40 people with mild-to-moderate acne all using topical benzoyl peroxide plus adapalene, a moisturiser with ceramides and niacinamide significantly improved non-inflammatory, inflammatory and total acne lesions on that side of the face versus a hydrophilic cream after 8 weeks, and decreased cutaneous irritation.
Who it applies to: People on topical anti-acne medication who add a moisturiser alongside treatment, in a split-face, double-blind, randomized design for 8 weeks.
Study limits: All participants used prescription/OTC anti-acne drugs (5% benzoyl peroxide + 0.1% adapalene). TEWL, hydration, sebum, pH and other biophysical measures stayed close between the two creams. This is adjunctive care.
- Skin effect Human trial Certainty: Moderate Primary source
In a 12-week randomized, double-blind half-face study, a combination of 4-hexylresorcinol and niacinamide improved hyperpigmentation spots (L*), the appearance of fine lines and wrinkles, and skin firmness significantly more than niacinamide alone.
Who it applies to: Chinese adults using the combination cream twice daily for 12 weeks in a split-face design.
Study limits: Industry-funded (Unilever R&D); part of the evidence comes from in-vitro melanocyte and 3D skin models.
- Skin effect Human trial Certainty: Low Primary source
A facial moisturiser containing niacinamide improved stratum corneum barrier function and skin hydration, measured instrumentally, in people with rosacea over four weeks of twice-daily use.
Who it applies to: A leave-on facial moisturiser, applied twice daily for four weeks, in adults with rosacea.
Study limits: The tested article was a finished moisturiser. Fifty participants, one centre, four weeks. The study measured barrier function and hydration.
- Skin effect Human trial Certainty: Low Primary source
In a randomized split-face controlled trial in people with rosacea-associated erythema and sensitive skin, a dermocosmetic containing mineralizing water, probiotic fractions, hyaluronic acid and niacinamide significantly improved erythema at day 15 (p<0.01) and day 30 (p<0.001), with skin erythema, tightness, dryness, hydration and TEWL improving versus the untreated side (p<=0.05).
Who it applies to: Facial erythema, tightness, dryness, hydration and TEWL over 30 days.
Study limits: The comparator is usual skin care / an untreated half-face.
- Skin effect Human trial Certainty: Low Primary source
In an open randomized, vehicle-controlled trial of 48 people with mild-to-moderate facial seborrheic dermatitis, 4% nicotinamide cream once daily for 12 weeks reduced the combined erythema/scaling/infiltration score by 75% from baseline versus 35% with the vehicle (p<0.05).
Who it applies to: Combined clinical score of erythema, scaling and infiltration over 12 weeks.
Study limits: Open-label.
- Skin effect Human trial Certainty: Low Primary source
In 30 women with melasma or post-inflammatory hyperpigmentation, a serum combining lotus sprout extract, tranexamic acid and niacinamide reduced skin tone unevenness by 38% and 33% respectively over 16 weeks (P < 0.008).
Who it applies to: Women with melasma or PIH, 70% with Fitzpatrick skin types IV-VI, applying the serum twice daily for 16 weeks.
Study limits: 30 participants; "skin tone unevenness" is a sponsor-defined endpoint.
- Skin effect Human trial Certainty: Moderate Primary source
In 88 women with sensitive skin, a face cream containing Centella asiatica leaf extract, ceramide NP and panthenol lowered the SS-10 symptom score by 66% at week 2 and 76% at week 4, with irritation, tautness, itching and redness all significantly reduced.
Who it applies to: Chinese women with sensitive skin applying the cream to the whole face, followed up at day 2, weeks 1, 2 and 4.
Study limits: Observational and self-controlled.
- Skin effect Human trial Certainty: Moderate Primary source
In 38 children with atopic dermatitis, a cream containing linoleic acid, 5% dexpanthenol and ceramide improved SCORAD significantly more than a 5% urea cream after 4 weeks (P = 0.043); both groups improved from baseline.
Who it applies to: Children with mild-to-moderate atopic dermatitis applying the cream twice daily for 4 weeks in a randomised, double-blind, bilateral paired design.
Study limits: Both interventions were non-prescription moisturisers: this is emollient / basic skin care. Small sample (37 completed); stratum corneum hydration and time to remission stayed close between groups.
- Skin effect Human trial Certainty: Moderate Primary source
In 110 people with facial sensitive skin, a cream containing panthenol used twice daily for 28 days significantly increased stratum corneum moisture and reduced erythema index, redness (a* value) and transepidermal water loss.
Who it applies to: People with facial sensitive skin applying the cream twice daily for 28 days.
Study limits: Panthenol was combined with prebiotics and a probiotic lysate.
- Skin effect Human trial Certainty: Low Primary source
After facial non-ablative fractional laser treatment, a panthenol mask lowered the erythema and pigmentation indices on days 3, 7 and 14 against a saline dressing, raised stratum corneum moisture, and reduced transepidermal water loss over the same days. Sebum content was also higher in the mask group on days 7 and 14.
Who it applies to: Skin recovering from 1550 nm and 1927 nm non-ablative fractional laser on the face. Both groups received standard post-procedure care.
Study limits: The mask also contained madecassoside and bisabolol. It is one trial of 60 people, all recovering from the same procedure, and the published grant list includes L'Oreal Dermatological Beauty China (La Roche-Posay).
- Skin effect Human trial Certainty: Low Primary source
In a randomized, investigator-blind, split-face trial of 40 Asian acne patients, a moisturizer containing 4-t-butylcyclohexanol, licochalcone A, ceramide and panthenol improved facial hydration more than a traditional moisturizer (p=0.001) and produced lower dryness scores (p=0.021) over 4 weeks.
Who it applies to: Facial hydration and investigator-rated dryness over 4 weeks.
Study limits: All participants were on prescription acne therapy (including oral isotretinoin), so the dryness is drug-induced; both sides used a moisturizer, so this is a comparison between two moisturisers; acne lesion counts decreased equally on both sides.
- Sensitization Review article Certainty: Low Primary source
Panthenol is treated as non-allergenic, this review argues that frequent exposure, especially on damaged skin, can produce hypersensitivity to it. The likely route is a delayed (type IV) contact reaction; immediate and mixed reactions remain possible. Proposes patch testing with the patient's own product and with panthenol 5% in petrolatum.
Who it applies to: People who use panthenol products repeatedly, particularly those with atopic or damaged skin - the group the author says is most exposed.
Study limits: A single-author narrative review. The mechanism it proposes is stated as likely. Read it as a reason to keep panthenol on the list of possible allergens.
- Legal limits Official legal text Certainty: High Primary source
The EU Scientific Committee on Consumer Safety concluded in 2016 that 2-phenoxyethanol is safe as a preservative at a maximum of 1.0%, which is the limit already set in Annex V/29 of the EU Cosmetics Regulation. It estimated a margin of safety of about 50 for children.
Who it applies to: Phenoxyethanol used as a preservative in cosmetic products, at or below 1.0%.
Study limits: The dossier behind the conclusion was submitted by Cosmetics Europe, the industry association, and the committee lowered the default toxicokinetic factor from 4.0 to 1.0 on its way to the 1.0% conclusion. The final opinion kept 1.0%.
Related skin concerns
Skin concerns with evidence for ingredients on this list.
Formula history
1 version of this formula on record.